Improving the care of patients who have treatment-resistant depression: The promise of the PCORnet mood network

Journal of Clinical Psychiatry

Volumn 76, Issue 4, 2015, Pages e528-e530

  Nierenberg, Andrew A ^a,b   Sylvia, Louisa ^a,b   Doederlein, Allen ^c   Edgman Levitan, Susan ^a   Muskin, Alies ^d   Jewell, Lucinda ^c   Walker, Muffy ^e   Goodman, Dan ^a   Farahbakhsh, Massoud ^a   Hearing, Casey ^a   Tovey, Roberta ^a   Deckersbach, Thilo ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Depression and Bipolar Support Alliance (DBSA)   (United States)

^d Anxiety and Depression Association of America   (United States)

^e International Bipolar Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; QUETIAPINE; ANTIDEPRESSANT AGENT;

CLINICAL EFFECTIVENESS; COMORBIDITY; DECISION MAKING; DEPRESSION; DRUG EFFICACY; HUMAN; MOOD DISORDER; NOTE; PATIENT CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; SUICIDAL BEHAVIOR; TREATMENT OUTCOME; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; MALE; PATIENT ATTITUDE; PSYCHOLOGY;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; MALE; PATIENT ACCEPTANCE OF HEALTH CARE;

EID: 84932119406     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14com09570     Document Type: Note

References (16)

1. Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015;76(4):e487-e498.
2. Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301(8):831-841. doi:10.101/jama.209.205 PubMed
3. Montgomery K. How Doctors Think: Clinical Judgment and the Practice of Medicine. New York, NY: Oxford University Press; 2005.
4. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): A tool to help trial designers. J Clin Epidemiol. 2009;62(5):464-475. doi:10.1016/j.jclinepi.208.12.01 PubMed
5. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? a STAR∗D report. Am J Psychiatry. 2009;166(5):599-607. doi:10.176/api.ajp.208.08071027 PubMed
6. Friedman ES, Calabrese JR, Ketter TA, et al. Using comparative effectiveness design to improve the generalizability of bipolar treatment trials data: contrasting LiTMUS baseline data with pre-existing placebo controlled trials. J Affect Disord. 2014;152-154:97-104. doi:10.1016/j.jad.2013.05.052 PubMed
7. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol. 2009;62(5):499-505. doi:10.1016/j.jclinepi.209.01.012 PubMed
8. Kraemer HC, Wilson GT, Fairburn CG, et al. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002;59(10):877-883. doi:10.101/archpsyc.59.10.87 PubMed
9. Kraemer HC, Schultz SK, Arndt S. Biomarkers in psychiatry: methodological issues. Am J Geriatr Psychiatry. 2002;10(6):653-659. doi:10.1097/01942-20210-04 PubMed
10. Rush AJ, Fava M, Wisniewski SR, et al; STAR∗D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR∗D): rationale and design. Control Clin Trials. 2004;25(1):119-142. doi:10.1016/S0197-2456(03)012-0 PubMed
11. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a singleblind randomized study. Am J Psychiatry. 2011;168(7):689-701. doi:10.176/api.ajp.201.101645 PubMed
12. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003;53(11):1028-1042. doi:10.1016/S06-323(03)0165-3 PubMed
13. Nierenberg AA, Sylvia LG, Leon AC, et al; Litmus Study Group. Lithium treatment-moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. Clin Trials. 2009;6(6):637-648. doi:10.17/17407450934739 PubMed
14. Nierenberg AA, Sylvia LG, Leon AC, et al; Bipolar CHOICE Study Group. Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): A pragmatic trial of complex treatment for a complex disorder. Clin Trials. 2014;11(1):114-127. doi:10.17/174074513512184 PubMed
15. Wang PS, Ulbricht CM, Schoenbaum M. Improving mental health treatments through comparative effectiveness research. Health Aff (Millwood). 2009;28(3):783-791. doi:10.137/hlthaf.28.3.783 PubMed
16. McMurry AJ, Murphy SN, MacFadden D, et al. SHRINE: enabling nationally scalable multi-site disease studies. PLoS ONE. 2013;8(3):e55811. doi:10.1371/journal.pone.0581 PubMed